| Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers | Molecular systems biology |  | | 2025 | 75 | 57 |
|
| Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder | Molecular therapy. Nucleic acids | | | 2025 | 40 | 68 |
|
| Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties | Heliyon | | | 2024 | 298 | 142 |
|
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | | | 2024 | 140 | 397 |
|
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | | | 2023 | 116 | 203 |
|
| Cells of the tumor microenvironment speak the Wnt language | Trends in molecular medicine |  | | 2023 | 138 | 4 |
|
| Chlorin endogenous to the north pacific brittle star ophiura sarsii for photodynamic therapy applications in breast cancer and glioblastoma models | Biomedicines | | | 2022 | 512 | 220 |
|
| Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation | Acta neuropathologica communications | | | 2022 | 287 | 171 |
|
| Marine natural products from the russian pacific as sources of drugs for neurodegenerative diseases | Marine drugs | | | 2022 | 175 | 205 |
|
| Pediatric encephalopathy: cinical, biochemical and cellular insights into the role of Gln52 of GNAO1 and GNAI1 for the dominant disease | Cells | | | 2021 | 414 | 280 |
|
